Selvita appoints Dr. Nicolas D. Beuzen as Chief Scientific Officer and Member of the Management Board

14-May-2008

Selvita Sp. z o.o. announced the appointment of Dr. Nicolas D. Beuzen as its Chief Scientific Officer and Member of the Management Board. Dr. Beuzen will oversee all Selvita's drug research projects.

Selvita

Dr. Nicolas D. Beuzen

After the first experience in 2002 as a Strategic Database Manager at Sanofi Pasteur MSD, Dr Beuzen joined in 2003 OPi Pharmaceuticals (now EUSA) as Project Manager. His activities included work on pre-clinical onco-haematology drug candidates (monoclonal antibodies and small molecules) as well as stage II-IV development in onco-haematology, CNS and metabolism. In 2006 he moved to India as Project Coordinator at Ethypharm, where he managed an international cross-functional team on the 'New Drug Delivery' portfolio of the French company. He holds a PhD in Molecular Biology from the University of Glasgow (United Kingdom) , B.Sc. in Applied biology - biotechnology and protein engineering from London South Bank University (United Kingdom). He is also a graduate of Université Jean Moulin (Lyon III) in Lyons (France) where he obtained his DESS (eq. M.A.) degree in Marketing of pharmaceutical products.

Other news from the department people

More news from our other portals

So close that even
molecules turn red...

See the theme worlds for related content

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

View topic world
Topic world Antibodies

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous